Mitochondria and cell nucleus dual-targeting metal platinum complex as well as preparation method and application thereof
By designing a platinum complex DP-Pt that targets both mitochondria and the cell nucleus, the problem of existing platinum-based anticancer agents being unable to treat mutant p53 tumors has been solved. This approach achieves highly efficient inhibition of mutant p53 tumor cells and reversal of drug resistance, demonstrating significant antitumor activity and biocompatibility.
Patent Information
- Application Number
- CN202411026152.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-30
AI Technical Summary
Existing platinum-based metal anticancer agents are ineffective in treating tumor cells carrying TP53 gene mutations, leading to cisplatin resistance, and cannot reverse the oncogenic GOF phenotype of the mutant p53 protein.
A platinum metal complex that targets both mitochondria and the cell nucleus was designed and synthesized through specific ligand modification and reaction conditions to form a platinum metal complex DP-Pt that can target both cells. Utilizing its planar square geometry and the positive charge properties of its hydrated form, it can attract nuclear DNA and target mitochondria, thereby inducing cell dysfunction and inhibiting DNA damage repair.
This complex can effectively inhibit the proliferation of mutant p53 tumor cells, achieve high cytotoxicity and antitumor activity by inducing mitochondrial dysfunction and DNA damage repair, degrade Mutp53 protein, overcome drug resistance, and has a wide range of applications.
Smart Images

Figure CN118955573A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a metal platinum complex, in particular to a mitochondria and cell nucleus dual-targeted metal platinum complex, and also to a preparation method and application of the complex. Background Art
[0002] Subcellular organelles, such as the nucleus, mitochondria, and lysosomes, are important organelles within cells and are responsible for maintaining biological processes such as cell proliferation and differentiation, signal transduction, and energy metabolism. Mitochondria are known as the "energy factories" of cells. They also play an important role in many important cellular processes. Mitochondria synthesize ATP to support various cellular processes and participate in many other important functions, including initiating apoptotic pathways, calcium metabolism, electron transfer, and reactive oxygen generation. The nucleus is the control center of eukaryotic cells, and it hosts most of the genetic material and various proteins involved in DNA replication and transcription. Many basic biological functions such as gene expression, cell differentiation, cell growth, and apoptosis occur near the nucleus. Due to its key role in cell growth and proliferation, the nucleus has been shown to be involved in carcinogenic mechanisms. Due to their roles in energy production and programmed cell death, these organelles have become major therapeutic targets in different diseases and conditions. Rationally designed organelle-targeted metal complexes can directly destroy subcellular structures, which further activate certain cell death pathways, thereby improving treatment efficiency and even overcoming drug resistance. In recent years, the design of anticancer metal complexes that specifically target organelles to achieve precise drug delivery and avoid possible toxic side effects of drugs has attracted widespread attention.
[0003] The discovery of cisplatin and its clinical success represent a milestone in the development of anti-tumor drugs. As a key transcription factor, p53 regulates the transcription of target genes and is a downstream effector molecule of intracellular DNA damage, playing a key role in the mechanism of action of cisplatin. However, more than 50% of human cancers carry TP53 gene mutations, which lead to the production of dysfunctional mutant p53 proteins, which are highly stable and accumulated in tumor cells, showing carcinogenic GOF (gain of function) phenotypes, such as promoting tumor proliferation, survival and migration. Literature reports that changes in TP53 are associated with the development of sensitivity and resistance of cancer cells to cisplatin, and accurate p53 stability and activity will reduce the cisplatin resistance of tumor cells. At present, no platinum-based metal anticancer agents can successfully treat mutant p53 tumors and reverse cisplatin resistance. Therefore, it is urgent to develop degrader materials for overcoming cisplatin resistance. Summary of the invention
[0004] Purpose of the invention: The purpose of the present invention is to provide a metal platinum complex that is dual-targeted to mitochondria and cell nuclei, and also to provide a preparation method and application of the above-mentioned complex.
[0005] Technical solution: The present invention discloses a metal platinum complex that is dual-targeted to mitochondria and cell nuclei, and the structural formula is as follows:
[0006]
[0007] The preparation method of the above-mentioned complex comprises the following steps:
[0008] (1) dissolving 3-(9,9-dimethylacridin-10(9H)-yl)-5-(pyridin-4-yl)phenol, triphenylphosphine and K2CO3 in acetone, stirring and refluxing under an argon atmosphere; after the reaction, centrifuging and collecting the supernatant, evaporating the solvent and then recrystallizing to obtain a triphenylphosphine-modified ligand;
[0009]
[0010] (2) mixing the triphenylphosphine-modified ligand obtained in step (1), cisplatin and DMF, stirring and reacting in the dark; after the reaction, removing the solvent by rotary evaporation, re-dissolving and recrystallizing to obtain a metal platinum complex that is dual-targeted to mitochondria and nuclei;
[0011]
[0012] Wherein, in step (1), the molar ratio of 3-(9,9-dimethylacridin-10(9H)-yl)-5-(pyridin-4-yl)phenol, triphenylphosphine and K2CO3 is 1:1.3:3.
[0013] Wherein, the reflux reaction temperature is 45-50°C and the time is 10-12h; preferably 50°C and 12h.
[0014] The molar ratio of the triphenylphosphine-modified ligand to cisplatin is 1:1.
[0015] Wherein, in step (2), the reaction temperature is 50-55°C and the reaction time is 48-60h; preferably 55°C and 60h.
[0016] Wherein, in step (2), the re-dissolving is carried out by using hot methanol.
[0017] Wherein, in step (1) or (2), the recrystallization is performed by using ether and dichloromethane for at least 3 times.
[0018] The above-mentioned mitochondrial and cell nucleus dual-targeted metal platinum complex can also be used in the preparation of anti-tumor drugs or anti-tumor drug components.
[0019] The tumor is a human lung cancer cell; the metal platinum complex inhibits the proliferation of tumor cells and induces mitochondrial dysfunction in cancer cells and inhibits DNA damage repair.
[0020] Principle of the invention: The metal platinum complex of the present invention that targets both mitochondria and nuclei has a planar square geometric configuration that promotes ligand replacement. The chlorine ligand in the complex is replaced by water molecules to form a hydrate. At this time, the positive charge carried by the center of the complex can attract it to the negatively charged nuclear DNA, which is also the reason why it induces nuclear DNA damage. In addition, the metal platinum complex of the present invention contains a mitochondrial targeting ligand, which can achieve the goal of inducing cell mitochondrial dysfunction while targeting mitochondria, thereby inhibiting DNA damage repair and inhibiting the proliferation of tumor cells.
[0021] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: (1) The complex DP-Pt of the present invention can solve the problem that platinum-based metal anticancer agents cannot treat mutant p53 tumors; (2) The complex DP-Pt of the present invention exhibits high cytotoxicity to a variety of tumor cells, and its IC value for human lung cancer resistant cells (A549R) is 50 The value is 6.3uM, which can effectively inhibit the proliferation of tumor cells; (3) After entering the cell, the complex DP-Pt of the present invention achieves dual targeting of mitochondria and cell nucleus, and achieves good anti-tumor activity by inducing mitochondrial dysfunction in cancer cells and inhibiting DNA damage repair; (4) The complex DP-Pt of the present invention can also induce mitochondrial autophagy and necroptosis in tumor cells, and has a wide range of application scenarios. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The subcellular organelle distribution (A) and cellular uptake quantitative diagram (B) of the complex DP-Pt of the present invention;
[0023] Figure 2 The figure (A) and the immunofluorescence figure (B) of the degradation of Mutp53 protein by the complex DP-Pt of the present invention;
[0024] Figure 3 The complex DP-Pt of the present invention induces A549R cells to produce reactive oxygen species;
[0025] Figure 4 This is a diagram showing the depolarization of mitochondria in A549R cells induced by the complex DP-Pt of the present invention;
[0026] Figure 5 This is a diagram of the mitochondrial autophagy of A549R cells induced by the complex DP-Pt of the present invention;
[0027] Figure 6This is a diagram showing DNA damage and cell necrosis of A549R cells induced by the complex DP-Pt of the present invention. DETAILED DESCRIPTION
[0028] The technical scheme of the present invention is further described below in conjunction with the examples. The test materials used in the examples can all be purchased through conventional channels.
[0029] Example 1
[0030] The preparation method of the mitochondrial and nucleus dual-targeted metal platinum complex (DP-Pt) of the present invention comprises the following steps:
[0031] (1) Synthesis of compound DP-PPh3: DP-OH (3-(9,9-dimethylacridin-10(9H)-yl)-5-(pyridin-4-yl)phenol) (37.8 mg, 0.1 mmol), triphenylphosphine (62.2 mg, 0.13 mmol), and potassium carbonate (41.5 mg, 0.3 mmol) were added to a Shrek tube. 15 mL of acetone was used as a solvent, and the mixture was reacted overnight under argon gas at 50°C. After the reaction was completed, the supernatant was centrifuged and the solvent was evaporated and recrystallized with ether and dichloromethane for at least 3 times to obtain a yellow-brown oily product, named DP-PPh3, with a yield of about (62 mg, 80%). 1 H NMR(400MHz,Chloroform-d)δ(ppm):8.71-8.66(m,2H),7.94-7.85(m,7H),7.75(dtd,J=8.4,6.9 ,1.7Hz,4H),7.67(td,J=7.5,3.4Hz,5H),7.62-7.57(m,2H),7.49(dd,J=7.4,1.9Hz,2H),7.36(t ,J=1.9Hz,1H),7.23(d,J=1.7Hz,1H),6.98(dtd,J=15.5,7.3,1.7Hz,4H),6.35(dd,J=7.8,1.7Hz ,2H),4.26(t,J=5.7Hz,2H),4.03(s,2H),2.37-2.25(m,2H),1.91(q,J=7.7Hz,2H),1.72(s,6H).
[0032]
[0033] (2) Synthesis of complex DP-Pt: Dissolve silver nitrate in 3 mL of anhydrous DMF and add dropwise to a solution of cisplatin (30.0 mg, 0.1 mmol) dissolved in 6 mL of anhydrous DMF. React at 45°C in the dark. After overnight reaction, centrifuge to obtain 9 mL of clear solution, store in the dark and label it as solution A. Dissolve DP-PPh3 (77.6 mg, 0.1 mmol) in 3 mL of anhydrous DMF, then dissolve an equal amount of silver nitrate (17.0 mg, 0.1 mmol) in 3 mL of DMF and add dropwise to the DP-PPh3 solution with a syringe. React at 50°C in the dark under an argon atmosphere overnight to remove bromide ions. After the reaction, take the supernatant and label it as solution B. Take 3 mL of solution A prepared in the previous step and add it to solution B. React at 55°C in the dark for 60 h. Remove the solvent by rotary evaporation. Redissolve it in hot methanol and recrystallize it at least 3 times with ether and dichloromethane. An off-white product was obtained, named DP-Pt, with a yield of about (45.5 mg, 42%). 1 H NMR(400MHz,DMSO-d6)δ8.75(s,2H),8.06(s,3H),7.78(s,15H),7.55(s,5H),6.97(s,5H),6.21 (s,1H),4.79(s,5H),4.28(s,2H),4.19(d,J=8.7Hz,2H),1.96(s,2H),1.71(s,2H),1.64(s,6H).
[0034]
[0035] Comparative Example 1
[0036] A method for preparing a lysosome-targeted metal platinum complex (DM-Pt), comprising the following specific steps:
[0037] (1) Synthesis of compound DP-MOR: DP-OH (3-(9,9-dimethylacridin-10(9H)-yl)-5-(pyridin-4-yl)phenol) molecules, 4-(2-chloroethyl)morpholine and K2CO3 were dissolved in acetone; the mixture was stirred and refluxed under an argon protective atmosphere; after the reaction, the supernatant was obtained by centrifugation, and the crude product was purified by silica gel column chromatography using CH2Cl2 / MeOH as eluent to obtain a gray-brown product named DP-MOR; the yield was about (184.2 mg, 75%). 1H NMR (400MHz, DMSO-d6) δ8.63(d,J=5.5Hz,2H),7.83(d,J=6.2Hz,2H),7.64-7.38(m,4H),7.11-6.86( m,5H),6.27(d,J=8.1Hz,2H),4.25(t,J=5.7Hz,2H),3.57(t,J=4.7Hz,4H),2.73(s,2H),1.64(s,6H).
[0038] (2) Synthesis of complex DM-Pt: Dissolve silver nitrate in 3 mL of anhydrous DMF and add dropwise to a solution of cisplatin (30.0 mg, 0.1 mmol) dissolved in 6 mL of anhydrous DMF. React at 45°C in the dark. After overnight reaction, centrifuge to obtain 9 mL of clear solution, store in the dark and label it as solution A. Dissolve DP-MOR (49.1 mg, 0.1 mmol) in 3 mL of anhydrous DMF, then dissolve an equal amount of silver nitrate (17.0 mg, 0.1 mmol) in 3 mL of DMF and add dropwise to the DP-MOR solution with a syringe. React at 50°C in the dark under an argon atmosphere overnight to remove bromide ions. After the reaction, take the supernatant and label it as solution B. Take 3 mL of solution A prepared in the previous step and add it to solution B. React at 55°C in the dark for 60 h. Remove the solvent by rotary evaporation. Redissolve it in hot methanol and recrystallize it at least 3 times with ether and dichloromethane. A gray-brown product was obtained, named DM-Pt, with a yield of about (25.7 mg, 56%). 1 H NMR(400MHz, DMSO-d6)δ8.78(dd,J=38.6,6.1Hz,2H),8.09(d,J=22.5Hz,2H),7.82-7.43(m,6H),7.19(d,J=19.8Hz,2H), 6.95(dt,J=28.6,7.6Hz,5H),6.26-6.18(m,2H),4.66(s,2H),4.28(d,J=22.2Hz,2H),3.57(s,4H),1.64(d,J=6.4Hz,6H).
[0039] For the complex DP-Pt prepared in Example 1, an in vitro toxicity experiment on tumor cells was conducted:
[0040] The MTT method was used to determine the cytotoxicity of DP-Pt, DM-Pt, Cis-Pt, DP-PPh3 and DP-MOR to different tumor cells. 100 μL of cell suspension was added to 8×10 4The cells were inoculated in a 96-well plate at a density of 100 μL / mL. After incubation in an incubator overnight, a certain concentration gradient of the complex was added to the 96-well plate, the cells were incubated for 48 h, and then 20 μL of MTT was added to each well and incubated for another 4 h. All the culture medium was carefully removed, 150 μL of DMSO was added, the absorbance was measured with a microplate reader, and the cytotoxicity data was calculated using SPSS software.
[0041] Table 1. IC of complexes DP-Pt, DM-Pt, Cis-Pt, DP-PPh3 and DP-MOR 50 (μM) value
[0042]
[0043] The results showed that the complex DP-Pt had higher proliferation inhibitory activity on A549R cells than the compound DP-MOR, complex DM-Pt and Cis-Pt, indicating that the modification of the mitochondrial targeting group significantly increased the toxic activity against tumor cells; at the same time, the complex DP-Pt had higher selectivity for normal cells than DP-PPh3, and it had higher biosafety.
[0044] Application of subcellular organelle distribution and cellular uptake quantification of the complex DP-Pt:
[0045] Methods: The cellular uptake and organelle distribution of DP-Pt, DM-Pt and Cis-Pt by A549R cells were determined by ICP-MS. A549R cells were seeded in 10 mL culture dishes and incubated overnight. The medium was removed and replaced with fresh medium containing 10 μM complexes. After 6 h of incubation, the cells were collected and the nuclei, mitochondria and cytoplasm were extracted and digested using a mitochondrial / nuclear isolation kit. The platinum content in the samples was then determined by ICP-MS.
[0046] Subcellular organelle localization of complexes in uptake Figure 1 As shown, the results show that the complex DP-Pt is mainly distributed in mitochondria and cell nuclei.
[0047] For the complex DP-Pt prepared in Example 1, an experiment of degrading Mutp53 protein was carried out:
[0048] Western blotting experiment: A549R cells were inoculated in a 10mL culture dish and incubated overnight. The culture medium was removed and replaced with fresh culture medium containing 10μM complexes DP-Pt and Cis-Pt for 48h. All cells were collected in a 15mL centrifuge tube, washed twice with PBS, transferred to a 1.5mL centrifuge tube and lysed by adding 200-400μL cell lysis buffer. After lysis, the protein concentration was determined using a BCA protein assay kit. Equal amounts of protein were separated by electrophoresis on an SDS-PAGE gel and transferred to a PVDF membrane after separation. After transfer, the membrane was blocked in skimmed milk powder for 1-2h and incubated with specific antibodies at 4°C overnight with shaking. Wash with PBST, then incubate with the corresponding secondary antibody for another 1h at room temperature, wash 4 times with PBST, and use a chemiluminometer for immunoblotting luminescence imaging.
[0049] Or use immunofluorescence experiment: A549R cells were inoculated in 35mm confocal culture dishes and incubated overnight, and then DP-Pt and Cis-Pt were added for incubation for 48h. After fixing with 4% paraformaldehyde for 30min, wash three times with PBS. LC3, γ-H2AX, and p53 antibodies prepared with skim milk powder were added to the culture dish and incubated at 4°C overnight. After completing the skim milk powder blocking and PBS washing steps, the corresponding secondary antibodies were added and incubated for 1h. Finally, the cells were stained with DAPI (300nM) for 15min for the nucleus. DAPI was removed and washed three times with PBS. After completion, the cells were immediately observed with a confocal microscope (A1, Nikon, Japan), λ ex =488nm and λ em =530±20nm.
[0050] The results of the complex DP-Pt degrading Mutp53 protein are as follows Figure 2 As shown; the results showed that DP-Pt effectively degraded mutp53 protein, while cisplatin and DM-Pt had no effect on mutp53 protein. Figure 2 As shown in Figure B, the immunofluorescence phenomenon is consistent with the above results.
[0051] Application of the complex DP-Pt of the present invention in inducing A549R cells to produce reactive oxygen species:
[0052] Methods: Confocal microscopy was used to detect changes in reactive oxygen species in tumor cells. Confocal imaging: A549R cells were inoculated in a 35 mm confocal culture dish and incubated overnight, and then DP-Pt and Cis-Pt were added and incubated for 24 h. Subsequently, 10 μM DCF-DA reactive oxygen species probe was used for staining for 30 min and washed three times with PBS. After treatment, cells were observed using a confocal microscope (A1, Nikon, Japan). ex =488nm and λ em=530±20nm.
[0053] The results of the changes in reactive oxygen species in A549R cells induced by the complex DP-Pt are shown in Figure 3 As shown. The results showed that: in the presence of the control example, no significant green fluorescence was observed in A549R cells. However, after treatment with DP-Pt, a significant increase in green fluorescence was observed. Therefore, DP-Pt can significantly activate the overexpression of ROS.
[0054] Application of the complex DP-Pt of the present invention to induce mitochondrial depolarization of A549R cells:
[0055] Methods: Confocal microscopy was used to detect changes in mitochondrial membrane potential in tumor cells. Confocal imaging: A549R cells were inoculated in a 35 mm confocal culture dish and incubated overnight, and then DP-Pt and Cis-Pt were added and incubated for 24 h. Subsequently, the cells were stained with 10 μM JC-1 working solution for 30 min and washed 4 times with 1× buffer. After treatment, the cells were observed using a confocal microscope (A1, Nikon, Japan). JC-1 Monomers: λ ex =490nm,λ em =520±20nm; JC-1Aggregates: λ ex =525nm,λ em =580±20nm.
[0056] The results of the changes in mitochondrial membrane potential of A549R cells induced by the complex DP-Pt are shown in Figure 4 The results show that compared with the control example, after the complex treatment, it can be observed that the green fluorescence is significantly enhanced and the red fluorescence is significantly weakened, indicating that the complex DP-Pt can effectively induce a decrease in mitochondrial membrane potential.
[0057] Application of the complex DP-Pt of the present invention in inducing mitochondrial autophagy in A549R cells:
[0058] Methods: Confocal microscopy was used to detect the co-localization test of mitochondria and lysosomes in cells. Confocal imaging: A549R cells were inoculated in a 35 mm confocal culture dish and incubated overnight, and then 10 μM DP-Pt was added and incubated for 48 h. Subsequently, 25 nM LysoBlue probe was incubated for 30 min and washed 4 times with PBS. Then 500 nM MitoRed probe was incubated for 30 min and washed 4 times with PBS. After the treatment, the cells were photographed with a confocal microscope (A1, Nikon, Japan). .
[0059] The results of the complex DP-Pt inducing mitochondrial lysosome fusion in A549R cells are shown in Figure 5The results showed that the co-labeling degree of mitochondrial red probe and lysosomal blue probe in A549R cells treated with DP-Pt was significantly higher than that in the control group, which confirmed the occurrence of mitochondrial autophagy.
[0060] Application of the complex DP-Pt to induce DNA damage and necroptosis in A549R cells:
[0061] Methods: Western blotting (WB) was used to detect changes in the content of related proteins. A549R cells were inoculated in a 10 mL culture dish and incubated overnight. The culture medium was removed and replaced with fresh culture medium containing 10 μM complexes DP-Pt and Cis-Pt for 48 h. All cells were collected in a 15 mL centrifuge tube, washed twice with PBS, transferred to a 1.5 mL centrifuge tube and lysed with 200-400 μL cell lysis buffer. After lysis, the protein concentration was determined using a BCA protein assay kit. Equal amounts of protein were separated by electrophoresis on SDS-PAGE gel and transferred to a PVDF membrane after separation. After transfer, the membrane was blocked in skimmed milk powder for 1-2 h and incubated with specific antibodies at 4 ° C with shaking overnight. Washed with PBST, then incubated with the corresponding secondary antibody for another 1 h at room temperature, washed 4 times with PBST, and immunoblotting luminescence imaging was performed using a chemiluminometer.
[0062] The experimental results of the complex DP-Pt inducing DNA damage and necroptosis-related protein expression in A549R cells are shown in Figure 6 As shown. The results showed that compared with the control group, the marker protein γ-H2AX was significantly upregulated after cells were treated with the complex DP-Pt, and the inhibitory activity of PARP-1 may be one of the main reasons for preventing DNA damage repair. The marker protein RIP3 protein of cell necrosis was also upregulated in a concentration-dependent manner after treatment with the complex DP-Pt. These results collectively indicate that the complex DP-Pt induces DNA damage and necroptosis in A549R cells.
[0063] Therefore, the mitochondrial and nucleus dual-targeted metal platinum complex of the present invention can effectively inhibit the proliferation of human tumor cells, induce mitochondrial and DNA damage in tumor cells, and induce cancer cell death through mitochondrial autophagy and necrosis; in addition, the complex of the present invention can degrade mutant p53 protein, thereby eliminating the acquired functional phenotype associated with mutant p53, including significantly inhibiting tumor growth, invasion and drug resistance, and has broad application prospects.
Claims
1. A metal platinum complex dual-targeted to mitochondria and nucleus, characterized in that: The structural formula of the complex is shown below:
2. A method for preparing the complex according to claim 1, characterized in that: The following steps are involved: (1) dissolving 3-(9,9-dimethylacridin-10(9H)-yl)-5-(pyridin-4-yl)phenol, triphenylphosphine and K2CO3 in acetone, stirring and refluxing under an argon atmosphere; after the reaction, centrifuging and collecting the supernatant, evaporating the solvent and then recrystallizing to obtain a triphenylphosphine-modified ligand; (2) mixing the triphenylphosphine-modified ligand obtained in step (1), cisplatin and DMF, stirring and reacting in the dark; after the reaction, removing the solvent by rotary evaporation, re-dissolving and recrystallizing to obtain a metal platinum complex that is dual-targeted to mitochondria and nuclei; 3. The preparation method according to claim 2, characterized in that: In step (1), the molar ratio of 3-(9,9-dimethylacridin-10(9H)-yl)-5-(pyridin-4-yl)phenol, triphenylphosphine and K2CO3 is 1:1.3:
3.
4. The preparation method according to claim 2, characterized in that: In step (1), the reflux reaction is carried out at a temperature of 45-50° C. and for a time of 10-12 h.
5. The preparation method according to claim 2, characterized in that: In step (2), the molar ratio of the triphenylphosphine-modified ligand to cisplatin is 1:
1.
6. The preparation method according to claim 2, characterized in that: In step (2), the reaction temperature is 50-55°C and the reaction time is 48-60h.
7. The preparation method according to claim 2, characterized in that: In step (2), the re-dissolving is carried out by using hot methanol.
8. The preparation method according to claim 2, characterized in that: In step (1) or (2), the recrystallization is performed by using ether and dichloromethane for at least 3 times.
9. Use of the mitochondria- and nucleus-dual-targeted metal platinum complex according to claim 1 in the preparation of antitumor drugs or antitumor drug components.
10. The use according to claim 9, characterized in that: The tumor is a human lung cancer cell.
Citation Information
Patent Citations
Mitochondrial targeting compound with aggregation-induced emission property and synthesis method and application thereof
CN113956292A
